# Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Canonical URL: https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-financial-results-and-provide-business-update
Ticker: ALLO
Company: Allogene Therapeutics
Source: Allogene Therapeutics
Published: 2026-05-06 12:30 EST
Original Source URL: https://ir.allogene.com
## Summary

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT / 5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for

## Article Body
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT / 5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for
## Recent Company News
- 2026-05-28 21:02 EST — [Allogene Therapeutics Announces Planned CEO Succession](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession) — Source: Allogene Therapeutics
- 2026-05-26 12:30 EST — [Allogene Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Allogene Therapeutics
- 2026-05-13 20:02 EST — [Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-05-06 12:30 EST — [Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-first-quarter-financial-results-and-provide-business-update) — Source: Allogene Therapeutics
- 2026-04-21 12:30 EST — [Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-expands-pivotal-phase-2-alpha3-trial-to-south-korea-and-australia) — Source: Allogene Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)